China's First Alzheimer's Drug Enters US Trials To Much Fanfare
China's first domestically developed Alzheimer’s drug inches closer to US market as FDA approves trials with Green Valley's GV-971.
You may also be interested in...
The company remains confident in US FDA approval for the first disease-modifying Alzheimer’s drug based on current data, but Biogen needs more time to complete the BLA filing.
A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.
More countries are joining the US to put national security interests over globalization, moving the production of medicines, medical supplies and protective equipment closer to home. The calls to repatriate manufacturing and reduce reliance on China will profoundly change how health products are supplied worldwide in the post-coronavirus era.